Watchful Waiting Has Lasting QOL Benefit in Rectal Cancer - Medscape

Martin T. King, MD, PhD, compares his 3-year hyaluronic acid spacer results with prior hydrogel data and walks through the practical factors, sculpting, apical placement, reversibility, that shape his own product choice. In this video, Martin T. King, MD, PhD, describes what the 3-year data add to the evidence base: a continued reduction in late grade 2 or higher GI toxicity, outcomes he says carry meaningful implications for patients.1 He acknowledges some ongoing debate about what proportion of patients are truly susceptible to these toxicities and says further research is needed to better define that population, but argues that minimizing this risk across all patients could still be of considerable value. Comparing these 3-year results with previously published data, he notes that the reduction in late grade 2 or higher GI toxicity is consistent with earlier findings from a PEG hydrogel spacer trial, even though that trial used conventionally fractionated radiation therapy rather than the hypofractionated regimen used in his study. He describes the overall agreement in toxicity outcomes as reassuring.